Corporate

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity

NEWARK, Delaware, January 10, 2024/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is rapidly expanding its mass spectrometry capacity, adding 13 LC-MS machines in just 15 months at their laboratories in Newark, Delaware (USA) and Groningen, The Netherlands (NL). […]

QPS Significantly Enhances Mass Spectrometry Laboratory Capacity Read More »

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

NEWARK, Delaware, Dec. 14, 2023/BUSINESS WIRE/ — QPS Holdings, LLC (QPS), a global contract research organization (CRO) that provides discovery, preclinical, bioanalysis, clinical trials, and clinical research services, is reinforcing its focus on qualitative and quantitative bioanalysis of biotherapeutics in Europe. QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development Read More »

QPS Holdings, LLC Expands Operations in Springfield, Missouri

SPRINGFIELD, Missouri, Dec. 4, 2023/BUSINESS WIRE/ — QPS Holdings, LLC, a global contract research organization, has expanded operations in Springfield, Missouri. The new facilities include a clinical (safety) laboratory, an updated self-contained pharmacy, and a new dedicated space to build and ship clinical trial kits. The 2,750-square-foot facility is fully operational as of the fall

QPS Holdings, LLC Expands Operations in Springfield, Missouri Read More »

QPS Opens Additional Preclinical Research Facility In Taipei, Taiwan

TAIPEI, Taiwan, Nov. 15, 2022 /PRNewswire/ — QPS, a global contract research organization, recently opened a second preclinical research facility in Taipei, Taiwan. The 2,793-square-foot facility will facilitate a research expansion into additional toxicology studies and a newly launched capability in pharmacology studies. The new facility will be operational in December 2022 and will give

QPS Opens Additional Preclinical Research Facility In Taipei, Taiwan Read More »

QPS Further Enhances Its Global Medical, Regulatory and Biotech CRO Services Capabilities

NEWARK, Del., Aug. 26, 2022 /PRNewswire/ — QPS, a leading global contract research organization (CRO), continues to expand and align its full service preclinical, bioanalysis and clinical capabilities with enhanced offerings across the medical, regulatory and biotech divisions. With these enhanced global capabilities, QPS is satisfying the need for agility, flexibility, and speed in the

QPS Further Enhances Its Global Medical, Regulatory and Biotech CRO Services Capabilities Read More »

Lipum has entered a partnership with QPS Netherlands B.V. for its first clinical trial with SOL-116

Press release: Umeå, March 9, 2022. Lipum AB (publ) announce that the company has entered into an agreement with QPS Netherlands BV for the first-in-man phase I-study of the drug candidate SOL-116. Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of

Lipum has entered a partnership with QPS Netherlands B.V. for its first clinical trial with SOL-116 Read More »

QPS Holdings LLC Announces a New Director of Neuropharmacology

Dr. Manuela Prokesch will lead the Neuropharmacology department of QPS Austria GmbH from January 1, 2022. QPS Holdings LLC announced that Dr. Prokesch, currently Associate Director of Neuropharmacology, has been selected as the new Director of Neuropharmacology, assuming the position on January 1, 2022. Prior to her role as Associate Director of Neuropharmacology, Dr. Prokesch

QPS Holdings LLC Announces a New Director of Neuropharmacology Read More »

QPS Supports COVID-19 Vaccine Development In Taiwan

Newark, Delaware, July 30, 2021 – QPS, a global contract research organization (CRO) focused on bioanalytics and clinical trials, is honored to have collaborated with Medigen Vaccine Biologics Corporation to complete toxicology studies necessary for the development of a COVID-19 vaccine. Researchers at the Center of Toxicology and Preclinical Sciences (CTPS) at QPS Taiwan completed

QPS Supports COVID-19 Vaccine Development In Taiwan Read More »

QPS Awarded Five 2021 CRO Leadership Awards

Newark, Delaware, June 2, 2021 – QPS, a GLP/GCP-compliant and CLIA-certified contract research organization (CRO) delivering discovery, preclinical, and clinical drug development services since 1995, was honored with five 2021 CRO Leadership Awards, presented by Clinical Leader and Life Science Leader. Recognized by its customers for exceeding their expectations, QPS received awards in five core

QPS Awarded Five 2021 CRO Leadership Awards Read More »

QPS Missouri Projected to Pay $1 Million to Local Participants

Clinical Research Studies Support Economic Growth and Development During A Pandemic, While Making a Global Difference Springfield, Missouri; November 12, 2020 – QPS announced today that the Springfield campus is projecting to pay out more than $1 Million in stipends to area clinical research participants during the 4th Quarter of 2020. Of that $1 Million

QPS Missouri Projected to Pay $1 Million to Local Participants Read More »

QPS Awarded Two 2020 CRO Leadership Awards

QPS is a GLP/GCP-compliant and CLIA-certified contract research organization (CRO) delivering discovery, preclinical, and clinical drug development services since 1995. An award-winning leader focused on bioanalytics and clinical trials, QPS, has been awarded two 2020 CRO Leadership Awards by Life Science Leader magazine. Recognized by its customers for exceeding their expectations, QPS was honored in

QPS Awarded Two 2020 CRO Leadership Awards Read More »

QPS Expands Its Global Footprint with New Facilities in the Netherlands, India, and China

Newark, Delaware, September 18, 2019 – QPS, a leading contract research organization (CRO), continues to expand its global footprint with new clinics in the Netherlands and India and a new bioanalytical facility in China. With these state-of-the-art establishments, QPS is satisfying a need for new facilities in the global drug development community. QPS Netherlands recently celebrated the

QPS Expands Its Global Footprint with New Facilities in the Netherlands, India, and China Read More »

Scroll to Top